Plus Therapeutics, Inc. (PSTV) Balance Sheet

The contraction in total assets suggests that the company is struggling to maintain a stable capital base while navigating the high costs of radiopharmaceutical research. Investors should monitor whether this downward trend in asset value persists, as it may indicate an increasing reliance on external financing to cover operational deficits.

The current ratio of 2.27 in 2026Q1 appears superficially healthy, but this metric is heavily influenced by the timing of grant-related liabilities and does not reflect the underlying cash burn. The rapid decline in cash reserves warrants further investigation into the company's ability to fund its upcoming clinical milestones without further dilutive equity offerings.

The negative retained earnings reflect years of accumulated losses that have eroded the company's book value. This trend suggests that the firm's capital structure is heavily skewed toward equity financing, which may continue to pressure existing shareholders as the company seeks to bridge its funding gaps.